Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.